Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Gene therapy represents a transformative approach in the treatment of breast cancer, leveraging the ability to modify genetic material within a patient's cells to combat this complex disease. This innovative strategy aims to address the underlying genetic mutations responsible for tumorigenesis, providing a potential curative solution where traditional therapies may fall short. Alfa Cytology is dedicated to advancing gene therapy development specifically for breast cancer.
In recent years, with the vigorous development of gene editing technology and biomedical materials science, the dawn of gene therapy has arrived. Thanks to great advances in gene editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR) and gene editing technology, gene therapy can be delivered in a more convenient and precise manner. The concept of gene therapy was developed based on the theory that correcting cancer-related mutations can control or inhibit the growth of cancer cells and improve patient prognosis. Gene delivery systems, including viral and non-viral vectors, also determine their clinical safety and efficiency. Breast cancer (BC) is one of the most lethal cancers in women, and using DNA- or RNA-based gene therapy has the potential to address key candidate genes in BC.
Fig.1 Ex vivo and in vivo gene therapy. (Dastjerd NT, et al, 2022)
Gene therapy development is a young field facing a wide range of challenges, including a dynamic regulatory environment, pre-existing and treatment-induced immunity to viral vectors. Alfa Cytology's preclinical gene therapy development services ensure the comprehensive services and expertise needed to create solutions for every gene therapy development challenge, from IND-enabled testing to commercialization, ready to advance your development program.
DNA-Based Gene Therapy Development Services
Our DNA-based gene therapy services focus on the delivery of therapeutic genes to correct genetic defects or to introduce new functionalities in breast cancer cells. Key components of our DNA-based services include:
RNA-Based Gene Therapy Development Services
Our RNA-based gene therapy services focus on leveraging RNA molecules to modulate gene expression in breast cancer. These services include:
Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC gene therapy development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.
Reference